Skip to search formSkip to main contentSkip to account menu

GL-ONC1

Known as: GLV-1h68 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Light-Emitting Oncolytic Vaccinia Virus GL-ONC1

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Silk‐elastin‐like protein polymer matrix for intraoperative delivery of an oncolytic vaccinia virus
Oncolytic viral efficacy may be limited by the penetration of the virus into tumors. This may be enhanced by intraoperative… 
2015
2015
Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma
Although early stage cholangiocarcinoma (CC) can be cured by surgical extirpation, the options for treatment of advanced stage CC… 
2014
2014
Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently.
2012
2012
Effective oncolytic vaccinia therapy for human sarcomas.
2011
2011
Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68
Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy. In this study… 
2010
2010
Regression of Human Prostate Tumors and Metastases in Nude Mice following Treatment with the Recombinant Oncolytic Vaccinia Virus GLV-1h68
Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy. In the current… 
2009
2009
Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent
Mammary cancers together with cancers of the skin account for about 60% of the total cancers occurring in dogs. The veterinary… 
Highly Cited
2009
Highly Cited
2009
Oncolytic vaccinia therapy of squamous cell carcinoma
BackgroundNovel therapies are necessary to improve outcomes for patients with squamous cell carcinomas (SCC) of the head and neck… 
Highly Cited
2008
Highly Cited
2008
Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma.
Malignant pleural mesothelioma (MPM) is a fatal disease with a median survival of less than 14 months. For the first time, a… 
Highly Cited
2008
Highly Cited
2008
Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo.
CONTEXT Anaplastic thyroid carcinoma (ATC) is a fatal disease with a median survival of only 6 months. Novel therapies are needed… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)